Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.56.

A number of research analysts recently weighed in on the stock. Piper Sandler lowered their target price on shares of Akoya Biosciences from $6.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. BTIG Research lowered Akoya Biosciences from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. Craig Hallum decreased their target price on Akoya Biosciences from $7.50 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday, August 6th. Morgan Stanley downgraded Akoya Biosciences from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $4.00 to $3.00 in a research note on Tuesday, August 6th. Finally, JPMorgan Chase & Co. lowered shares of Akoya Biosciences from an "overweight" rating to a "neutral" rating in a report on Tuesday, August 6th.

Institutional Trading of Akoya Biosciences

A number of large investors have recently added to or reduced their stakes in the company. Regal Investment Advisors LLC grew its holdings in shares of Akoya Biosciences by 64.3% in the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company's stock valued at $44,000 after purchasing an additional 7,340 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Akoya Biosciences by 16.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company's stock worth $158,000 after buying an additional 9,429 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Akoya Biosciences by 87.4% in the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company's stock worth $845,000 after buying an additional 144,903 shares in the last quarter. Silvercrest Asset Management Group LLC bought a new stake in shares of Akoya Biosciences in the 1st quarter worth about $2,724,000. Finally, Vanguard Group Inc. raised its position in shares of Akoya Biosciences by 3.3% during the 1st quarter. Vanguard Group Inc. now owns 1,454,288 shares of the company's stock valued at $6,821,000 after buying an additional 46,131 shares in the last quarter. Institutional investors own 79.42% of the company's stock.

Akoya Biosciences Stock Performance

Shares of NASDAQ AKYA traded down $0.05 during midday trading on Friday, hitting $3.17. 59,094 shares of the company's stock traded hands, compared to its average volume of 106,069. The firm has a fifty day moving average of $2.84 and a 200 day moving average of $2.66. The stock has a market capitalization of $156.92 million, a price-to-earnings ratio of -2.58 and a beta of 1.34. Akoya Biosciences has a 1 year low of $1.88 and a 1 year high of $6.31. The company has a debt-to-equity ratio of 3.43, a quick ratio of 1.98 and a current ratio of 2.73.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.